

Immunomodulation of experimental autoimmune encephalomyelitis by helminth ova immunization

Diane Sewell¹, Zhu Qing¹, Emily Reinke¹, David Elliot², Joel Weinstock²,
Matyas Sandor¹ and Zsuzsa Fabry¹

¹Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53706, USA

²Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA

Keywords: experimental autoimmune encephalomyelitis, *Schistosoma mansoni*, STAT6, T_h1, T_h2

Abstract

Experimental autoimmune encephalomyelitis (EAE) is an animal model for multiple sclerosis (MS) characterized by chronic inflammatory demyelination of the central nervous system (CNS). The pathology of EAE involves autoimmune CD4⁺ T_h1 cells. There is a striking inverse correlation between the occurrence of parasitic and autoimmune diseases. We demonstrate that in mice with *Schistosoma mansoni* ova immunization, the severity of EAE is reduced as measured by decreased clinical scores and CNS cellular infiltrates. Disease suppression is associated with immune deviation in the periphery and the CNS, demonstrated by decreased IFN- γ and increased IL-4, transforming growth factor- β and IL-10 levels in the periphery, and increased frequency of IL-4 producing neuroantigen-specific T cells in the brain. *S. mansoni* helminth ova treatment influenced the course of EAE in wild-type mice, but not in STAT6-deficient animals. This indicates that STAT6 plays a critical role in regulating the ameliorating effect of *S. mansoni* ova treatment on the autoimmune response, and provides the direct link between helminth treatment, T_h2 environment and improved EAE. As some intestinal helminthic infections induce minimal pathology, they might offer a safe and inexpensive therapy to prevent and/or ameliorate MS.

Introduction

Autoimmunity and infectious disease do not occur in isolation. The immune repertoire is shaped by environmental exposures, resulting in a pre-existing immune status in every individual (1,2). This pre-existing immune status influences T_h1- and T_h2-mediated immune responses (3–5). The lack of serious childhood infections might impair the development of the T_h1/T_h2 balance, resulting in susceptibility to chronic immune-mediated diseases (4). This hygiene hypothesis was strongly supported by describing an inverse association between different infectious diseases and atopy (6–10), and has been recently extended to include applicability to autoimmunity (11,12).

Autoimmunity in the central nervous system (CNS) is a complex event, induced and maintained by activated CD4 T_h cells. Following activation in the periphery, T cells can enter the CNS and persist if they encounter their cognate antigens (13).

There are at least two subsets of antigen-experienced T_h cells. T_h1 clones secrete primarily IL-2, IFN- γ and tumor necrosis factor (TNF)- β , and promote inflammation, delayed-type hypersensitivity and cellular immunity. T_h2 clones produce IL-4, -5, -6, -10 and -13 cytokines, and promote B cell activation and antibody production, and eosinophil and mast cell differentiation. The existence of functionally polarized human T cell responses is also established (14).

CNS-infiltrating T_h cells in experimental autoimmune encephalomyelitis (EAE) are proinflammatory cytokine-producing T_h1 cells (15–17). In contrast, oral tolerance to myelin basic protein and natural recovery from EAE is associated with up-regulation of T_h2 cytokines, IL-4 and TGF- β (18–20). Adoptive transfer of neuroantigen-specific T_h2 cell lines has not resulted in EAE (21). A greatly increased T_h1 effector cell mass in multiple sclerosis (MS) patients has recently been indicated by the presence of a highly

The first two authors contributed equally to this work

Correspondence to: Z. Fabry; E-mail: zfabry@facstaff.wisc.edu

Transmitting editor: A. Falus

Received 29 July 2002, accepted 2 October 2002

IFN- γ -polarized, IL-5⁻ cytokine profile of proteolipid protein (PLP)-reactive T cells (22).

The contribution of factors inducing T_h differentiation into the polarized T_h1 or T_h2 pathway has been controversial. The cytokine profile of innate immunity evoked by different pathogens, the nature of the peptide ligand, the activity of co-stimulatory molecules and the context of varied host genetic backgrounds have been suggested to play a role in this process. Polarized T_h1- and T_h2-type responses play different roles in protection, with T_h1 effective in defense against intracellular pathogens and T_h2 against intestinal nematodes. T_h1 responses predominate in organ-specific autoimmune disorders, acute allograft rejection and some chronic inflammatory disorders. T_h2 responses predominate in transplantation tolerance, chronic graft versus host disease, systemic sclerosis, allergy and atopic disorders. The development of a polarized T_h1 or T_h2 immune response is also influenced by cross-talk between T_h1 and T_h2 subsets. T_h1 cytokines (IFN- γ and IL-2) inhibit the production of T_h2 cytokines (IL-4, IL-5 and IL-10), whereas T_h2 cytokines inhibit the production of T_h1 cytokines (23). A balanced production of these cytokines is crucial in maintaining a healthy immune system (24–29).

We addressed the possibility of T_h1/T_h2 cross-talk in a natural immune environment, whether 'T_h2 preconditioning' of mice would influence the course of T_h1-mediated autoimmunity in EAE. Falcone *et al.* previously addressed the possibility that a T_h2 response against an exogenous, non-self antigen could shift the cytokine profile of encephalitogenic T cells from an inflammatory T_h1 to a protective T_h2 type by releasing IL-4 in the microenvironment (30).

The cross-regulation of T_h1/T_h2 balance is documented in several infectious disease contexts. Helminthic parasites, which induce T_h2-type inflammation, can modulate T_h1 immune responses to unrelated concomitant parasitic, bacterial or viral infections. Patients infected with *Schistosoma mansoni* mount a T_h2-type response to tetanus toxoid instead of the expected T_h1 or T_h0 response (31,32). Ethiopian immigrants with a high incidence of helminthic infections show a propensity to respond to phytohemagglutinin with T_h2, not T_h1 cytokines (33). Infection of mice with *S. mansoni* delays clearance of vaccinia virus and alters response to sperm whale myoglobin (34,35). Mice develop a T_h2-type response when infected with *Brugia malayi*, or when immunized with filarial extract that modulates the T_h1 response to non-parasite or microbial antigen. The murine intestinal nematode, *Nippostrongylus brasiliensis*, stimulates T_h2 activity and delays kidney graft rejection in rats, most likely by cross-regulatory suppression of T_h1 activity (36).

These findings have important implications. They suggest that persons harboring helminths are apt to mount a diminished T_h1 response when challenged with other antigens. It has been also suggested that helminth infections actively dampen atopy in humans (37–41).

We have developed a model to study the effect of T_h2 preconditioning on the course of EAE using *S. mansoni* ova immunization. Schistosome infections are mild, self-limiting and common in areas of poor sanitation. MS is very rare in these areas, as opposed to the higher incidence of MS and other autoimmune diseases in areas with stringent hygienic

standards (42,43). This difference suggests a correlation between an environmental factor (hygienic standards) and T_h1-type autoimmune diseases. We demonstrate significant protection from EAE in *S. mansoni* ova preimmunized animals, indicating that parasitic infections can influence the course of CNS autoimmunity. A direct link between schistosome ova preconditioning, ameliorated EAE and the role of T_h2 cytokines in this process is demonstrated by a shift to T_h2 cytokines in the periphery and the CNS, and the lack of this effect in STAT6-deficient mice. As some intestinal helminthic infections induce minimal pathology, this approach might offer a new therapeutic option to prevent or ameliorate MS.

Methods

Animals

Female SJL and C57BL6 mice aged 4–6 weeks were purchased from Jackson Laboratories (Bar Harbor, ME). STAT6^{-/-} mice on a C57BL6 background were generated by Dr Michael Grusby (Harvard University, Boston, MA). All mice were maintained in a VA or UW animal facility. EAE induction was initiated between 6 and 8 weeks of age. All procedures were performed under an approved protocol in compliance with UW Animal Care Guidelines.

Reagents

Murine PLP_{139–151} (HSLGKKGHPDKF) and murine myelin oligodendrocyte glycoprotein (MOG)_{35–55} (MEVGWRSPPFSR-VVHLYRNGK) peptides were synthesized by CyberSyn (Lenni, PA). Pertussis toxin was purchased from List Biological (Campbell, CA). Anti-CD3 (145.2C11) was purified as described previously (44). These reagents for ELISA were purchased from PharMingen (San Diego, CA): purified rat anti-mouse IL-2 (clones JES-1A12 and JES-5H4), IL-4 (clone BVD4-24G2), IL-5 (TRFK4 and TRFK5), IFN- γ (clones R4-6A2 and XMG1.2), IL-10 (SXC-1 and JES-16E3) and TGF- β (A75-2.1 and A75-3.1) mAb; recombinant mouse IL-2, IL-4, IL-5, IL-10, TGF- β and IFN- γ . Streptavidin-conjugated alkaline phosphatase and substrate MUP (4-methylumbelliferyl phosphate) were purchased from Molecular Probes (Eugene, OR).

EAE Induction

EAE was induced in SJL mice by s.c. flank immunization with 400 μ g PLP_{139–151} peptide emulsified in complete Freund's adjuvant (CFA) containing 1 mg/ml H37Ra *Mycobacterium tuberculosis* (Sigma, St Louis, MO). Seven days later, mice received a second immunization with the same protocol. Pertussis toxin, 200 ng (List Biological) was injected i.v. on days 0, 2 and 7. In C57BL6 and STAT6^{-/-} mice, EAE was induced by a single s.c. injection of 100 μ g MOG_{35–55} peptide emulsified in CFA containing 5 mg/ml H37Ra *M. tuberculosis*; 200 ng pertussis toxin was injected i.p. on days 0 and 2.

Animals were assessed clinically according to standard criteria: 0, normal; 1, loss of tail tone; 2, hind limb weakness; 3, hind limb paralysis; 4, hind limb and forelimb paralysis; 5, moribund or death. Mice with a clinical score of 4 for >1 day were euthanized.

S. mansoni egg isolation and pretreatment

S. mansoni eggs were isolated from infected hamsters as described (45). Two weeks before EAE induction, 10,000 *S. mansoni* eggs were injected i.p. to the experimental groups. A second dose of *S. mansoni* eggs was injected 4 days prior to EAE induction using 5000 eggs i.p. and 5000 s.c. in the flank where PLP peptide was injected. The same volume of PBS was injected in the control groups.

When *S. mansoni* ova treatment was initiated following induction of EAE, 20,000 eggs were injected i.p. to five mice per group, on day 2, 7, 10 or 14 post EAE induction.

Tissue processing and histology

For histology and cytokine analysis, mice from experimental and control groups were sacrificed before EAE induction (day 0), at the onset of the disease (day 15) and after recovery (day 45). Brains and spinal cords were used for histological studies. Tissues were fixed in 10% paraformaldehyde, embedded in paraffin, sectioned and stained with H & E.

Cytokine analysis by ELISA

Cytokine concentrations were measured in supernatants from anti-CD3-treated (2 µg/ml), 48-h cultures of isolated spleen cells. Costar 3590 96-well plates (Corning, Corning, NY) were coated with primary antibodies, including: anti-IFN-γ (R4-6A2), IL-5 (TRFK5), TGF-β (A75-2.1) and IL-10 (JES5-2A5), all from PharMingen, and IL-4 (11B11) from NIH (Bethesda, MD). All coating antibodies were used at 2 µg/ml concentration except IL-10 and TGF-β, used at 4 µg/ml. After blocking with TBS/1% BSA, serially diluted standards and triplicate samples were added to the plates. Samples were incubated at 4°C overnight. Plates were washed with TBS/Tween and biotinylated secondary antibodies were added. Plates were incubated for 2 h at room temperature. Detection antibodies used were IFN-γ (XMG1.2), IL-4 (BVD6-24G2), TGF-β (A75-3.1) and IL-10 (SXC-1) (PharMingen), and IL-5 (TRFK-4) prepared in-house from hybridoma. Secondary antibodies were all used at a 1 µg/ml concentration except IL-10, used at 2 µg/ml. Unbound secondary antibody was washed out and a streptavidin-alkaline phosphatase conjugate (1:2000 in TBS/Tween/BSA) was added. Plates were developed using MUP fluorescent substrate and read at 360/465 nm on the HTS 7000 plate reader (Perkin Elmer, Norwalk, CT).

ELISPOT assays

ImmunoSpot 96-well plates (Cellular Technology, Cleveland, OH) were coated overnight at 4°C with 100 µl/well coating antibodies [IFN-γ (R4-6A2) 4 µg/ml or IL-4 (11B11) 2 µg/ml]. Plates were blocked with PBS/1% BSA and washed. Spleen cells (10⁶/well) or brain cells (10³/well) were plated in HL-1 medium supplemented with 1% L-glutamine. Mitomycin C-treated spleen cells from a naive SJL mouse (5 × 10⁵/well) were added to the brain cell wells to act as antigen-presenting cells. PLP_{139–151} peptide antigen (2 µg/ml), concanavalin A (5 µg/ml) or media were added to triplicate wells. Plates were incubated overnight at 37°C. Biotinylated secondary antibodies [IFN-γ (XMG 1.2) 4 µg/ml or IL-4 (BVD6-2462) 2 µg/ml; PharMingen] diluted in PBS/Tween/BSA were added to the appropriate plates, at 100 µl/well. Plates were

incubated overnight at 4°C. Streptavidin-horse radish peroxidase, 1:2000 in PBS/Tween/BSA, 100 µl/well was added and plates were incubated for 90 min at room temperature. Colored spots were developed by addition of AEC 200 µl/well (Pierce, Rockford, IL). Plates were scanned on an ImmunoSpot analyzer (Cellular Technology, Cleveland, OH) and quantified by Image analysis software.

Intracellular cytokine staining and FACS

Spleens cells were isolated as previously described (46). Cells were washed and resuspended at 10⁷ cells/ml in RPMI for culture with Golgistop (PharMingen) and lipopolysaccharide (LPS; Sigma, St Louis, MO).

Brains were removed from PBS perfused animals to HBSS and minced using sterile scissors. Samples were transferred to Medicon inserts and processed in a Medimachine for 30 s. The cell suspension was centrifuged at 1000 g for 7 min. Cells were re-suspended in 2 ml 50% Percoll (Pharmacia, Piscataway, NY) and overlaid with 30% Percoll. Gradients were centrifuged at 1500 g for 30 min at 4°C. Interfaces were removed, washed and resuspended in RPMI (47).

Spleen or CNS cells were incubated at 1 × 10⁵ (CNS) or 1 × 10⁷ (spleen) cells/ml in RPMI with or without LPS at 5 µg/ml, in the presence of GolgiStop (PharMingen) for 4 h. Cells were surface stained with CD11b antibody (Mac1-Cy5, M1/70) in the presence of anti-CD16 (2.4G2) blocking reagent. Cells were fixed and permeabilized with Cytofix/Cytoperm (PharMingen), and stained with IL-12-phycoerythrin, tumor necrosis factor-α-phycoerythrin or the appropriate isotype control (PharMingen). Samples were analyzed on a FACSCalibur (BD, Mansfield, MA) using CellQuest software as previously described (44,46).

Statistical analysis

Statistical analysis was performed using JMP3.2 (Professional Edition) statistical software. Group mean clinical scores were analyzed by paired *t*-tests. Repeated measures of ANOVA were used for comparison of the mean clinical scores. Mean maximum scores were compared by Student's *t*-test and ANOVA. Cytokine concentrations were analyzed by Student's *t*-test.

Results

S. mansoni ova preimmunization improves the clinical course of EAE in SJL mice

To determine whether *S. mansoni* ova preimmunization would modify the course of EAE, 6-week-old female SJL/J mice were injected i.p. with 10,000 ova 14 days, and 5000 ova i.p. and 5000 s.c. 4 days prior to EAE induction. This protocol induces a very strong T_H2-type immune response as measured primarily by ELISA for IL-4 cytokines (48–50). EAE was induced by s.c. injection of PLP_{139–151} peptide in CFA. Animals were monitored daily for the development of clinical signs of EAE. Symptoms appeared on day 11 in control EAE groups and peaked at days 15–17 (Fig. 1A). This type of EAE induction results in the development of a relapsing disease, closely approximating the course of MS. We detected a relapse starting at day 30 post-induction, reaching a second




Fig. 1. *S. mansoni* eggs reduce the severity of EAE. SJL mice were pretreated with PBS (A) or *S. mansoni* eggs (B) 14 and 4 days before induction of EAE with PLP_{139–151} emulsified in CFA. The mice were monitored for clinical signs of EAE. Results are presented as mean clinical score \pm SEM (error bars) from three independent experiments ($n = 30$). ($P < 0.0001$ as determined by paired *t*-test.)

peak at days 32–33 with a mean clinical score of 1.0 ± 0.08 (Fig. 1A). In three independent experiments, mice preimmunized with *S. mansoni* ova demonstrated a significantly less severe disease course as compared to control EAE mice, indicated by lower daily mean clinical scores ($P < 0.0001$; Fig. 1B.). The onset of disease occurred on day 13 with a mean maximum clinical score of 1.0 ± 0.06 .

To explore the possibility that schistosome ova treatment can influence the course of EAE when given following initiation of autoimmune response, *S. mansoni* ova were injected on days 2, 7, 10 and 14 following EAE induction. Figure 2 shows that schistosome ova treatment significantly delayed the development of EAE when ova were applied in the initiation (day 2), but not in the effector (days 7–14), phase of the disease.

Together, these studies suggest that schistosome ova preimmunization can modify the outcome of CNS autoimmunity.

Inflammatory cell recruitment to the CNS is significantly decreased in mice preconditioned with S. mansoni ova and induced for EAE

Cellular infiltration is a hallmark of EAE. To characterize whether the improved clinical score in EAE is reflected in decreased cellular infiltrates in schistosome ova-treated EAE animals, we induced EAE with or without schistosome ova immunization and examined the animals for histologic evidence of EAE. To study the maximum infiltration of CNS invading cells, tissues from the CNS were taken at day 17 after EAE induction. Figure 3 demonstrates the spinal cord and brain from control or schistosome ova-injected mice with EAE. Figure 3(A and C) demonstrates cellular infiltrates in the brain and spinal cord respectively of animals with EAE. Figure 3(B and D) shows significantly ameliorated cellular infiltration in the brain parenchyma and spinal cord of animals with EAE following *S. mansoni* ova immunization. Statistically significant differences in both number of infiltrated vessels and the




Fig. 2. *S. mansoni* ova treatment affects the clinical course of EAE. Five groups of 6-week-old female SJL/J mice were induced for EAE as described in Methods. One group was left untreated (open circles, $n = 32$). The other groups were treated with 20,000 i.p. injected *S. mansoni* ova at day 2 (filled squares, $n = 5$), 7 (filled triangles, $n = 4$), 10 (filled diamonds, $n = 5$) or 14 (crosses, $n = 5$) post-induction of EAE. Clinical scores were recorded daily beginning at day 7. Data is presented as mean clinical score \pm SEM. Error bars are shown only on untreated and day 2 treated groups for clarity. Animals treated at day 2 showed a significantly delayed onset and a milder clinical course than the untreated controls. At day 15 of EAE, clinical scores were significantly different between untreated and day 2 treated groups ($P < 0.02$). Animals that were treated later were less different from the untreated controls.

degree of infiltration between control and ova-treated mice is demonstrated in Table 1. Although eosinophils have been indicated in parasitic diseases, there were no eosinophils in the CNS of schistosome ova-treated animals (data not shown). This data indicates that *S. mansoni* ova preconditioning of experimental animals reduced inflammation in the CNS.

The effect of S. mansoni ova injection on cytokine production—up-regulation of IL-4 and down-regulation of IFN- γ cytokine production from spleen cells in mice following immunization with schistosome ova

It has been established that infestation with helminthic parasites induces a T_H2 -type response. Since T_H2 cytokines are important in the regulation of T_H1 cytokines (23), our next experiments characterized the cytokine profile of schistosome-treated and non-treated control mice, before and 15 days following EAE induction. Spleen cells were cultured with anti-CD3 for 48 h. The supernatants were assayed for IFN- γ , IL-4, IL-5, TGF- β and IL-10 production, (i) to ascertain that the resulting sensitization to the parasite antigens induced T_H2 cytokine production and (ii) to analyze the effect of ova treatment on autoimmune disease-induced animals. We analyzed cytokine production before (day 0) and 15 days following EAE induction. Spleen cells from schistosome ova-injected animals produced higher levels of all T_H2 cytokines tested, IL-4, TGF- β , IL-10 and IL-5, than unimmunized controls. At the same time, IFN- γ production was significantly inhibited in *S. mansoni*-treated animals, indicating T_H1 down-regulation in these mice (data not shown). The IFN- γ level remained down-regulated and the IL-4 level remained higher in ova-pretreated animals at day 15 post EAE induction (Fig. 4), indicating a continuing T_H2 bias in these mice. IL-5 production [previously demonstrated in SJL mice with induced EAE (16)] was not influenced by schistosome ova preimmunization.




Fig. 3. *S. mansoni* eggs reduce tissue infiltration in the CNS. The brains and spinal cords of control and *S. mansoni* egg-treated mice were processed for H & E staining. At the peak of EAE, control mice showed typical EAE lesions with massive perivascular infiltration and edema in brain (A) and spinal cord (C) (see arrows). In contrast, mice pretreated with *S. mansoni* eggs showed significantly less cellular infiltration, and there were fewer lesions in brain (B) and spinal cord (D) (see arrows). Representative of 10 animals in each group ($\times 200$). Statistical analysis of histologic findings is presented in Table 1.

Table 1.

	Control EAE	<i>S. mansoni</i> ova-pretreated EAE
Mean number of infiltrated vessels/ $\times 100$ field	1.35 \pm 0.56	0.25 \pm 0.10
Mean degree of infiltration	2.4 \pm 0.22	1.1 \pm 0.02
Total infiltrated vessels /20 fields mouse brain	27	5

Brains were harvested from control and *S. mansoni* ova-pretreated mice at day 35 of EAE. Sections were stained with H & E and examined for evidence of perivascular infiltrates. The number of vessels showing infiltrates from 20 non-overlapping, $\times 100$ fields per animal was counted. Each infiltrated vessel was graded from 1 to 4 based on the thickness of the perivascular infiltrate. A single layer of cells was scored as 1. Maximal infiltration was 4 or more cell layers thick and was scored as 4. *S. mansoni* ova-pretreated animals showed significantly fewer infiltrated vessels in their brain sections and infiltrates that were present were significantly smaller, $P < 0.05$.

These results imply that *S. mansoni* ova pretreatment of mice can shape the profile of autoimmunity-induced cytokine production.

S. mansoni ova injection does not affect the course of EAE in STAT6-deficient animals

To further explore the role of T_H2 cytokines in helminth-induced protection from EAE, we treated STAT6-deficient animals with schistosome ova and initiated EAE by MOG₃₅₋₅₅ peptide injection in CFA. Because the STAT6 knockout was available on the C57BL/6 background, we first needed to demonstrate protection from EAE by schistosome ova was also present in this mouse strain. Then we could ask whether STAT6 gene signaling was involved in schistosome ova protection. MOG peptide-induced EAE in C57BL/6 has been described

previously in C57BL/6 as a chronic, non-relapsing form of the disease, in contrast to the relapsing-relapsing form in SJL mice (51,52).

It has been demonstrated previously that the STAT6 pathway controls the differentiation of cells into a T_H2 phenotype and STAT6-deficient mice, with a predominantly T_H1 phenotype, demonstrate a more severe clinical course of EAE (53). *S. mansoni* ova preconditioning influenced the course of EAE (delayed response and attenuated chronic phase) in control C57BL6 mice, but not in the STAT6-deficient animals (Fig. 5). This data indicates that T_H2 cytokines, induced via STAT6 signaling, play a critical role in regulating the ameliorating effect of schistosome ova treatment in EAE, and provides the direct link between helminth treatment, T_H2 environment and improved EAE.




Fig. 4. Schistosome eggs precondition a T_H2 cytokine environment as measured by cytokine ELISA and the T_H2 bias is maintained after EAE induction. Spleen cells from SJL mice pretreated with PBS or *S. mansoni* ova at day 0 and 15 post-induction of EAE were cultured *in vitro* with anti-CD3 for 48 h. The level of cytokines was determined in culture supernatants by ELISA. (A) Increased levels of T_H2 cytokines and down-regulated IFN- γ as a result of schistosome ova immunization. White bars represent naive controls and black bars are age-matched *S. mansoni*-treated mice. Mean values from four mice per group were as follows: IFN- γ control 15,500 pg/ml, ova treated 3340 pg/ml; IL-4 control 80 pg/ml, ova treated 173 pg/ml; IL-5 control 269 pg/ml, ova treated 1072 pg/ml; IL-10 control 291 pg/ml, ova treated 707 pg/ml; TGF- β control 797 pg/ml, ova treated 1095 pg/ml. (B) The T_H2 cytokine bias is maintained at day 15 following EAE induction in *S. mansoni* ova-treated mice. Asterisks indicate that differences are significant at $P < 0.05$.

Cytokine ELISPOT analysis of antigen-specific T cells producing IFN- γ or IL-4 throughout the course of EAE, with or without prior S. mansoni ova immunization

To test whether *S. mansoni* ova immunization influences the antigen-specific T cell phenotype throughout the course of EAE, we characterized the CD4⁺ cells that were primed with PLP_{139–151} peptide with or without prior *S. mansoni* ova immunization. We evaluated the frequencies of cytokine-producing cells in mice with *S. mansoni* ova preimmunization; analyzed changes in the frequencies of cytokine-producing cells in mice with concurrent *S. mansoni* immunization and EAE; and compared the cytokine profile of cells isolated from central (brain parenchyma) and peripheral (spleen) T cell pools throughout the course of EAE with or without *S. mansoni* ova preimmunization.

Our first goal was to evaluate the appearance of PLP_{139–151}-specific T cells in the spleen and brain parenchyma in animals with ongoing EAE. On day 17 following EAE induction an

increased frequency of IFN- γ -producing cells is present in both spleen and brain (Fig. 6). This profile illustrates a highly polarized (IFN- γ^{high} IL-4^{low}) neuroantigen-specific T_H1 response in these experimental animals. When mice were preimmunized with *S. mansoni* ova, an increased frequency of cells carrying a more T_H2 -like phenotype (PLP specific, IFN- γ^{low} IL-4^{high}) was detected in the CNS. At the same time, an increased frequency of IL-4-producing cells with specificity for the PLP antigen could also be detected in the spleen; however, the frequency of neuroantigen-specific, IFN- γ^{high} cells did not decrease significantly. This emphasizes the shift to a more T_H2 -polarized immune response following *S. mansoni* ova immunization. The fact that the frequency of IFN- γ -producing cells was significantly decreased in the brain parenchyma, but not in the spleen, suggests local brain tissue regulation of cytokines during EAE.

These data illustrate the modifying effect of helminth ova immunization on the generation of autoimmune T cells.

Reduced IL-12, but unchanged TNF- α , expression by CD11b⁺ macrophages in the CNS tissue from mice with concomitant S. mansoni ova conditioning and EAE

Antigen-specific T cells constitute a very small portion of infiltrating leukocytes in EAE or MS lesions (47,54). Recruited inflammatory cells account for the majority of infiltrating cells and play a crucial role in CNS damage (55). Macrophage recruitment to the inflamed CNS is required for primed antigen-specific T cells to execute a T_H1 effector program in EAE (56).

Results described above suggested that *S. mansoni*-treated mice were deficient in recruiting and/or activating macrophages in the CNS during EAE due to decreased IFN- γ production in the brain tissue. To address this issue, mononuclear cells were isolated from CNS tissue of EAE and schistosome ova-pretreated EAE mice, and CD11b⁺ cells were analyzed with intracellular flow cytometry detecting IL-12 and TNF- α cytokines. Figure 7 illustrates that when compared with EAE controls, *S. mansoni* ova-treated mice showed a sharply reduced percentage of IL-12-producing, CD11b⁺ cells in the CNS during EAE attacks (29.4 ± 4.5 versus $15.3 \pm 3.1\%$, mean \pm SD, $n = 3$). In contrast, percentages of CD11b⁺ TNF- α^+ cells were relatively stable between the two groups of mice (41.3 ± 5.5 versus $40.4 \pm 2.5\%$, mean \pm SD, $n = 3$). These data suggest that IL-12 produced by CD11b⁺ macrophages is important in maintaining CNS autoimmune functions in EAE.

Discussion

The data described above demonstrate that pretreatment of mice with *S. mansoni* ova can attenuate the clinical course of actively induced EAE. Furthermore, schistosome ova treatment after induction of EAE significantly delayed the development clinical symptoms when ova were applied in the initiation, but not in the effector, phase of the disease. The recruitment of inflammatory cells in EAE lesions is also less severe in *S. mansoni* ova-treated mice than in untreated, EAE-induced groups. The amelioration of EAE is partly due to the effect of *S. mansoni* eggs on the T_H1/T_H2 balance in the hosts because splenocytes from schistosome egg-treated mice




Fig. 5. Schistosome ova pretreatment improves the clinical course of EAE in wild-type, C57BL6 mice but not in STAT6^{-/-} mice. Groups of C57BL/6 mice (A) and STAT6^{-/-} mice (B) were pretreated 14 and 4 days prior to induction of EAE (open circles) or not pretreated (filled diamonds). Animals were scored daily beginning at 6 days following disease induction. *S. mansoni* ova pretreatment improved the clinical course in C57BL6 mice (A). In the STAT6^{-/-} mice, schistosome ova showed no effect on the clinical course of EAE (B). This experiment suggests that induction of T_H2 cytokines through the STAT6 pathway contributes to the protection mediated by schistosome ova. Data represents one experiment of three (three to four mice per group) with similar results. There was no significant difference between schistosome ova-pretreated and untreated STAT6^{-/-} mice on any day in any of the three experiments. In the C57BL6 mice, schistosome ova pretreatment provided statistically significant protection on days 11–15 and 23–28, *P* < 0.05.




Fig. 6. ELISPOT analysis of IFN- γ - and IL-4-producing cells isolated from spleen and brain of SJL mice in response to *ex vivo* stimulation with PLP. EAE was induced in both naive and *S. mansoni* ova-pretreated groups, and cytokine-producing cells were quantified at the peak of disease, day 17. *S. mansoni* ova induced an increase in both IFN- γ - and IL-4-producing PLP antigen-specific spleen cells. In the brain, IL-4-producing cells were increased with a concomitant decrease in the IFN- γ cell frequency. (A) Representative wells demonstrating the pattern of increased T_H2 cytokine-producing cells in both brain and spleen as a result of ova pretreatment. (B) Mean counts \pm SE of six wells representing two animals at each condition. Media control values are presented to show specificity of the assay.




Fig. 7. Decreased IL-12 but unchanged TNF- α expression by CD11b⁺ cells in the CNS tissue from mice with *S. mansoni* ova pretreatment and EAE. SJL mice were pretreated with *S. mansoni* ova 14 and 4 days prior to EAE induction. EAE was induced by s.c. immunization with PLP_{135–151} peptide emulsified in CFA. Pertussis toxin was administered at day 0 and 2. Animals were analyzed at the peak of disease (day 17, control mean score 2.5 and *S. mansoni* ova pretreated mean score 1.0). Mononuclear cells were isolated from CNS and spleen tissues, and CD11b⁺ cells were analyzed with intracellular staining and flow cytometry, detecting IL-12 and TNF- α cytokines. Compared with EAE controls, *S. mansoni* ova-treated mice showed a sharply reduced percentage of CD11b⁺ cells producing IL-12 in the CNS during EAE attacks (29.4 ± 4.5 versus $15.3 \pm 3.1\%$, mean \pm SD, $n = 3$). In contrast, the percentage of CD11b⁺TNF- α ⁺ cells was similar between the two groups (41.3 ± 5.5 versus $40.4 \pm 2.5\%$, mean \pm SD, $n = 3$). Numbers are representative quadrant percentages.

secrete ~2.5 times more IL-4 cytokine than the control group before the induction of EAE. Local PLP antigen-specific CD4⁺ T cells from the CNS parenchyma exhibited a more significant modulation in their cytokine production than cells from the spleen. T cell responses against foreign antigen (*S. mansoni* ova immunization) and autoantigen (neural antigen: PLP) might be different. T cell responses to autoantigens might consist of low-affinity clones that remain following deletion of high-affinity auto-reactive T cells from the repertoire (57–60). T cell affinity has been implicated as an important factor in differentiation of T_H1/T_H2 cells (58,61). The possibility that IL-4 plays an important role in down-regulation of neural antigen-specific autoreactive cells in local tissues remains to be determined.

The direct association between T_H2 cytokines and helminth ova-induced protection from EAE was further suggested by the absence of any *S. mansoni* ova-induced protection from EAE in STAT6-deficient animals (Fig. 5). STAT6-deficient mice experience a more severe clinical course of EAE (53). *S. mansoni* ova preconditioning influenced the course of EAE in C57BL/6 mice, but not in STAT6-deficient animals, indicating that the STAT6 signaling plays a critical role in the ameliorating effect of schistosome ova treatment in EAE, and provides a direct link between helminth ova treatment, the T_H2 environment and improved EAE. Microbial compounds from *S. mansoni* have been shown to induce the development of DC2 and to promote development of T_H2 cells (62). The role of DC2 in helminth-induced protection from EAE remains to be explored.

Our data further emphasizes the role of IL-4 in the outcome and severity of EAE. IL-4 had been previously correlated with a polarized T_H2 immune response, crucial in the differentiation of T_H0 cells toward the T_H2 pathway (63–66). IL-4 knockout mice are defective in development of T_H2 cells (67). The disruption of the IL-4 gene in EAE-resistant strains such as BALB/c results in susceptibility to the induction of EAE (68). IL-4-deficient C57BL/6 mice, and to a lesser extent IL-4-deficient BALB/c mice, developed a more severe form of EAE, with more extensive pathologic involvement of the spinal cord, in parallel with an increased expression of pro-inflammatory cytokines in the CNS. EAE could also be inhibited by local delivery of IL-4 using retrovirus-transfected T cells (69). Systemic administration of IL-4 ameliorated the clinical course of EAE, and inhibited the production of IL-2 and TNF- α (T_H1) in SJL mice (70). These studies and ours suggest that a predominantly T_H2 cytokine microenvironment protects from development of EAE. Genetic predisposition toward T_H2 may also protect against the induction of EAE/MS (71).

The administration of helminth ova prior to EAE induction can lead to a significant degree of protection from disease, associated with a decreased number of IFN- γ -producing cells in the CNS and a greatly reduced level of leukocyte infiltration into the CNS. A strong T_H1 down-regulation in ova-preimmunized animals was detected by decreased IFN- γ production. The schistosome ova-induced T_H2 bias was maintained during EAE as indicated by the fact that IFN- γ remained down-regulated and IL-4 remained higher in ova-pretreated animals at day 15 of EAE.

IFN- γ has been shown to exacerbate MS (72–74). Antibodies to IFN- γ -inducing factor inhibited the production of IFN- γ and suppressed clinical EAE (75). However, IFN- γ treatments have also been shown to be protective against EAE in SJL mice (76) and IFN- γ knockout mice are still susceptible to EAE (77,78). Interestingly, IFN- γ has been shown to shape the immune invasion profile of leukocytes in the CNS by regulating chemokines (79). The possibility that the chemokine profile is changing in brain tissue due to schistosome ova treatment is currently under investigation in our laboratory.

Cross-regulation of T_H1/T_H2 cytokines is a paradigm that is currently under considerable scrutiny. There is ample evidence that this cross-regulation can exist in an infectious environment. Recently it has been shown that concurrent enteric helminth infection modulates inflammation and reduces helicobacter-induced gastric atrophy in mice (80). The same group demonstrated that the decrease of helicobacter-induced atrophy correlated with a reduction in mRNA for cytokines and chemokines associated with a T_H1-type inflammatory response. Furthermore, ongoing helminth (*S. mansoni*)-induced T_H2 response was shown to influence the outcome of a T_H1-inducing protozoan parasite *Toxoplasma gondii* infection by regulating the IFN- γ , TNF- α and NO response (81).

Because cytokines are often multifunctional and redundant, the results from cytokine knockout studies may be difficult to interpret, especially in a complicated disease like EAE (82). There are potential problems created by systemic administration of cytokines or antibodies to cytokines, including short half-life, systemic toxicity and access to target organs, especially the CNS. It is still unclear when, where and which cytokines or combinations of cytokines are needed due to the complicated function and cross-regulation of cytokines. In this study, *S. mansoni* eggs appear to induce a more physiological 'T_H2' microenvironment, which is inhibitory to the encephalitogenic T_H1 cell-mediated immune cascade. Changes in IL-12-producing cell phenotypes were also detected in treated animals (Fig. 7). *S. mansoni* ova-treated mice showed a sharply reduced percentage of CD11b⁺IL-12⁺ cells in the CNS during EAE. In contrast, percentages of CD11b⁺TNF- α ⁺ cells were relatively stable between the two groups.

These data suggest that IL-12 produced by CD11b⁺ macrophages is important in maintaining CNS autoimmune functions in EAE. *S. mansoni* ova might also regulate CD11b⁻, IL-12-producing cells. The identity of these cells is not known at this time; they certainly must be further characterized.

Individuals with predominant T_H2 responses against egg antigens have less severe egg-associated morbidity than those with predominantly T_H1 responses, thus a T_H2 predisposition is advantageous to the human host. We detected granulomas in the peritoneal cavity and the liver of ova-treated animals surrounded by healthy tissue, indicating minimal pathology induced by our treatment (data not shown). From an evolutionary perspective, people living in areas with a high prevalence of helminth infections might be positively selected because of their adaptively advantageous T_H2 responses. More importantly, many helminth parasites can survive in the host for many years (83). Long-term exposure to helminth antigens, especially during childhood, may have a deep impact on maturation of the host immune system.

MS patients have significantly fewer T_H2-mediated allergic diseases than would be expected (84). The reduced prevalence of allergic diseases in MS patients appears to be related to increased IL-12 production (85). Interestingly, helminth infections have also been suggested to protect people from allergic diseases. Some argue that under the pressure of helminth infections, allergens become minor stimuli to T_H2 effector cells such as mast cells (3).

In summary, the results of this study provide evidence that T_H2 diseases can modulate the development of T_H1 diseases by influencing the cytokine environment of immune competent cells. This study suggests that long-term infections with helminths in childhood might deeply impact the maturation of T_H1 and T_H2 cells. Exposure to helminths could be an important factor in suppressing the development of T_H1 cell-mediated autoimmune diseases in adulthood.

Acknowledgements

This work was supported by the National Multiple Sclerosis Society (grant RG3113A1/1 to Z. F.) and the National Institutes of Health (grant RO1 NS 37570-01A2 to Z. F.).

Abbreviations

CNS	central nervous system
CFA	complete Freund's adjuvant
EAE	experimental autoimmune encephalomyelitis
LPS	lipopolysaccharide
MOG	myelin oligodendrocyte glycoprotein
MUP	4-methylumbelliferyl phosphate
MS	multiple sclerosis
PLP	proteolipid protein
TGF	transforming growth factor

References

- Bell, E. B., Sparshott, S. M. and Bunce, C. 1998. CD4⁺ T-cell memory, CD45R subsets and the persistence of antigen—a unifying concept. *Immunol. Today* 19:60.
- Selin, L. K., Vergilis, K., Welsh, R. M. and Nahill, S. R. 1996. Reduction of otherwise remarkably stable virus-specific cytotoxic T lymphocyte memory by heterologous viral infections. *J. Exp. Med.* 183:2489.
- Cookson, W. O. and Moffatt, M. F. 1997. Asthma: an epidemic in the absence of infection? *Science* 275:41.
- Strachan, D. P. 1989. Hay fever, hygiene, and household size. *Br. Med. J.* 299:1259.
- Rook, G. A. and Stanford, J. L. 1998. Give us this day our daily germs. *Immunol. Today* 19:113.
- Yazdanbakhsh, M., van den Biggelaar, A. and Maizels, R. M. 2001. T_H2 responses without atopy: immunoregulation in chronic helminth infections and reduced allergic disease. *Trends Immunol.* 22:372.
- Shirakawa, T., Enomoto, T., Shimazu, S. and Hopkin, J. M. 1997. The inverse association between tuberculin responses and atopic disorder. *Science* 275:77.
- Matricardi, P. M., Rosmini, F., Ferrigno, L., Nisini, R., Rapicetta, M., Chionne, P., Stroffolini, T., Pasquini, P. and D'Amelio, R. 1997. Cross sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus. *Br. Med. J.* 314:999.
- Matricardi, P. M. and Bonini, S. 2000. High microbial turnover rate preventing atopy: a solution to inconsistencies impinging on the Hygiene hypothesis? *Clin. Exp. Allergy* 30:1506.
- Matricardi, P. M., Rosmini, F., Riondino, S., Fortini, M., Ferrigno, L., Rapicetta, M. and Bonini, S. 2000. Exposure to foodborne and

- orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study. *Br. Med. J.* 320:412.
- 11 Yazdanbakhsh, M., Kremsner, P. G. and van Ree, R. 2002. Allergy, parasites, and the hygiene hypothesis. *Science* 296:490.
 - 12 Sewell, D. L., Reinke, E. K., Hogan, L. H., Sandor, M. and Fabry, Z. 2002. Immunoregulation of CNS autoimmunity by helminth and mycobacterial infections. *Immunol. Lett.* 82:101.
 - 13 Hickey, W. F., Hsu, B. L. and Kimura, H. 1991. T-lymphocyte entry into the central nervous system. *J. Neurosci. Res.* 28:254.
 - 14 Romagnani, S. 1991. Human T_H1 and T_H2 subsets: doubt no more. *Immunol. Today* 12:256.
 - 15 Merrill, J. E. 1992. Proinflammatory and antiinflammatory cytokines in multiple sclerosis and central nervous system acquired immunodeficiency syndrome. *J. Immunother.* 12:167.
 - 16 Merrill, J. E., Kono, D. H., Clayton, J., Ando, D. G., Hinton, D. R. and Hofman, F. M. 1992. Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice [published erratum appears in *Proc. Natl Acad. Sci. USA* 1992;89:10562]. *Proc. Natl Acad. Sci. USA* 89:574.
 - 17 Merrill, J. E., Graves, M. C. and Mulder, D. G. 1992. Autoimmune disease and the nervous system. *Biochemical, molecular, and clinical update.* *Western J. Med.* 156:639.
 - 18 Fukaura, H., Kent, S. C., Pietrusewicz, M. J., Khoury, S. J., Weiner, H. L. and Hafler, D. A. 1996. Antigen-specific TGF-beta1 secretion with bovine myelin oral tolerization in multiple sclerosis. *Ann. NY Acad. Sci.* 778:251.
 - 19 Khoury, S. J., Hancock, W. W. and Weiner, H. L. 1992. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with down-regulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. *J. Exp. Med.* 176:1355.
 - 20 Khoury, S. J., Gallon, L., Chen, W., Betres, K., Russell, M. E., Hancock, W. W., Carpenter, C. B., Sayegh, M. H. and Weiner, H. L. 1995. Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness *in vivo*. *J. Exp. Med.* 182:357.
 - 21 Khoruts, A., Miller, S. D. and Jenkins, M. K. 1995. Neuroantigen-specific T_H2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector T_H1 cells. *J. Immunol.* 155:5011.
 - 22 Pelfrey, C. M., Rudick, R. A., Cotleur, A. C., Lee, J. C., Tary-Lehmann, M. and Lehmann, P. V. 2000. Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. *J. Immunol.* 165:1641.
 - 23 Paul, W. E. and Seder, R. A. 1994. Lymphocyte responses and cytokines. *Cell* 76:241.
 - 24 de Carli, M., D'Elia, M. M., Mariotti, S., Marcocci, C., Pinchera, A., Ricci, M., Romagnani, S. and del Prete, G. 1993. Cytolytic T cells with T_H1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. *J. Clin. Endocrinol. Metab.* 77:1120.
 - 25 Hahn, H. J., Lucke, S., Klöting, I., Volk, H. D., Baehr, R. V. and Diamantstein, T. 1987. Curing BB rats of freshly manifested diabetes by short-term treatment with a combination of a monoclonal anti-interleukin 2 receptor antibody and a subtherapeutic dose of cyclosporin A. *Eur. J. Immunol.* 17:1075.
 - 26 Olsson, T., Zhi, W. W., Hojberg, B., Kostulas, V., Jiang, Y. P., Anderson, G., Ekre, H. P. and Link, H. 1990. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. *J. Clin. Invest.* 86:981.
 - 27 Robinson, D. S., Hamid, Q., Ying, S., Tscopoulos, A., Barkans, J., Bentley, A. M., Corrigan, C., Durham, S. R. and Kay, A. B. 1992. Predominant T_H2-like bronchoalveolar T-lymphocyte population in atopic asthma. *N. Engl. J. Med.* 326:298.
 - 28 Romagnani, S. 1994. Lymphokine production by human T cells in disease states. *Annu. Rev. Immunol.* 12:227.
 - 29 Sher, A., Gazzinelli, R. T., Oswald, I. P., Clerici, M., Kullberg, M., Pearce, E. J., Berzofsky, J. A., Mosmann, T. R., James, S. L. and Morse, H. C. d. 1992. Role of T-cell derived cytokines in the down-regulation of immune responses in parasitic and retroviral infection. *Immunol. Rev.* 127:183.
 - 30 Falcone, M. and Bloom, B. R. 1997. A T helper cell 2 (T_H2) immune response against non-self antigens modifies the cytokine profile of autoimmune T cells and protects against experimental allergic encephalomyelitis. *J. Exp. Med.* 185:901.
 - 31 Sabin, E. A., Araujo, M. I., Carvalho, E. M. and Pearce, E. J. 1996. Impairment of tetanus toxoid-specific T_H1-like immune responses in humans infected with *Schistosoma mansoni*. *J. Infect. Dis.* 173:269.
 - 32 Pearce, E. J., La Flamme, A., Sabin, E. and Brunet, L. R. 1998. The initiation and function of T_H2 responses during infection with *Schistosoma mansoni*. *Adv. Exp. Med. Biol.* 452:67.
 - 33 Bentwich, Z., Weisman, Z., Moroz, C., Baryehuda, S. and Kalinkovich, A. 1996. Immune dysregulation in Ethiopian immigrants in Israel—relevance to helminth infections. *Clin. Exp. Immunol.* 103:239.
 - 34 Kullberg, M. C., Pearce, E. J., Hieny, S. E., Sher, A. and Berzofsky, J. A. 1992. Infection with *Schistosoma mansoni* alters T_H1/T_H2 cytokine responses to a non-parasite antigen. *J. Immunol.* 148:3264.
 - 35 Actor, J. K., Shirai, M., Kullberg, M. C., Buller, R. M., Sher, A. and Berzofsky, J. A. 1993. Helminth infection results in decreased virus-specific CD8⁺ cytotoxic T-cell and T_H1 cytokine responses as well as delayed virus clearance. *Proc. Natl Acad. Sci. USA* 90:948.
 - 36 Ledingham, D. L., McAlister, V. C., Ehigiator, H. N., Giacomantonio, C., Theal, M. and Lee, T. D. 1996. Prolongation of rat kidney allograft survival by nematodes. *Transplantation* 61:184.
 - 37 Araujo, M. I., Lopes, A. A., Medeiros, M., Cruz, A. A., Sousa-Atta, L., Sole, D. and Carvalho, E. M. 2000. Inverse association between skin response to aeroallergens and *Schistosoma mansoni* infection. *Int. Arch. Allergy Immunol.* 123:145.
 - 38 Lynch, N. R., Hagel, I., Perez, M., Di Prisco, M. C., Lopez, R. and Alvarez, N. 1993. Effect of anthelmintic treatment on the allergic reactivity of children in a tropical slum. *J. Allergy Clin. Immunol.* 92:404.
 - 39 Hagel, I., Lynch, N. R., DiPrisco, M. C., Lopez, R. I. and Garcia, N. M. 1993. Allergic reactivity of children of different socioeconomic levels in tropical populations. *Int. Arch. Allergy Immunol.* 101:209.
 - 40 Di Prisco, M. C., Hagel, I., Lynch, N. R., Barrios, R. M., Alvarez, N. and Lopez, R. 1993. Possible relationship between allergic disease and infection by *Giardia lamblia*. *Ann. Allergy* 70:210.
 - 41 van den Biggelaar, A. H., van Ree, R., Rodrigues, L. C., Lell, B., Deelder, A. M., Kremsner, P. G. and Yazdanbakhsh, M. 2000. Decreased atopy in children infected with *Schistosoma haematobium*: a role for parasite-induced interleukin-10. *Lancet* 356:1723.
 - 42 Kurtzke, J. F. 1995. MS epidemiology world wide. One view of current status. *Acta Neurol. Scand. Suppl.* 161:23.
 - 43 Kurtzke, J. F. 1997. *The Epidemiology of Multiple Sclerosis.* Chapman & Hall, London.
 - 44 Fabry, Z., Waldschmidt, M. M., Hendrickson, D., Keiner, J., Love-Homan, L., Takei, F. and Hart, M. N. 1992. Adhesion molecules on murine brain microvascular endothelial cells: expression and regulation of ICAM-1 and Lgp 55. *J. Neuroimmunol.* 36:1.
 - 45 Elliott, D. E. 1996. Methods used to study immunoregulation of schistosome egg granulomas. *Methods* 9:255.
 - 46 Fabry, Z., Waldschmidt, M. M., Van Dyk, L., Moore, S. A. and Hart, M. N. 1990. Activation of CD4⁺ lymphocytes by syngeneic brain microvascular smooth muscle cells. *J. Immunol.* 145:1099.
 - 47 Qing, Z., Sewell, D., Sandor, M. and Fabry, Z. 2000. Antigen-specific T cell trafficking into the central nervous system. *J. Neuroimmunol.* 105:169.
 - 48 Weinstock, J. V., Elliott, D., Metwali, A., Blum, A., Li, J., Qadir, K. and Sandor, M. 1999. Immunoregulation within the granulomas of murine *Schistosomiasis mansoni*. *Microbes Infect.* 1:491.
 - 49 Metwali, A., Elliott, D., Blum, A. M., Li, J., Sandor, M., Lynch, R., Noben-Trauth, N. and Weinstock, J. V. 1996. The granulomatous response in murine *Schistosomiasis mansoni* does not switch to T_H1 in IL-4-deficient C57BL/6 mice. *J. Immunol.* 157:4546.

- 50 Sacco, R. E., Jensen, R. J., Thoen, C. O., Sandor, M., Weinstock, J., Lynch, R. G. and Dailey, M. O. 1996. Cytokine secretion and adhesion molecule expression by granuloma T lymphocytes in *Mycobacterium avium* infection. *Am. J. Pathol.* 148:1935.
- 51 Okuda, Y., Okuda, M. and Bernard, C. C. 2002. Gender does not influence the susceptibility of C57BL/6 mice to develop chronic experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein. *Immunol. Lett.* 81:25.
- 52 Mendel, I., Kerlero de Rosbo, N. and Ben-Nun, A. 1995. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2^d mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. *Eur. J. Immunol.* 25:1951.
- 53 Chitnis, T., Najafian, N., Benou, C., Salama, A. D., Grusby, M. J., Sayegh, M. H. and Khoury, S. J. 2001. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. *J. Clin. Invest.* 108:739.
- 54 Cross, A. H., Cannella, B., Brosnan, C. F. and Raine, C. S. 1990. Homing to central nervous system vasculature by antigen-specific lymphocytes. I. Localization of ¹⁴C-labeled cells during acute, chronic, and relapsing experimental allergic encephalomyelitis. *Lab. Invest.* 63:162.
- 55 Ransohoff, R. M. 1999. Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines. *J. Neuroimmunol.* 98:57.
- 56 Huang, D. R., Wang, J., Kivisakk, P., Rollins, B. J. and Ransohoff, R. M. 2001. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. *J. Exp. Med.* 193:713.
- 57 Ashton-Rickardt, P. G. and Tonegawa, S. 1994. A differential-avidity model for T-cell selection. *Immunol. Today* 15:362.
- 58 Hosken, N. A., Shibuya, K., Heath, A. W., Murphy, K. M. and O'Garra, A. 1995. The effect of antigen dose on CD4⁺ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. *J. Exp. Med.* 182:1579.
- 59 Lehmann, P. V., Targoni, O. S. and Forsthuber, T. G. 1998. Shifting T-cell activation thresholds in autoimmunity and determinant spreading. *Immunol. Rev.* 164:53.
- 60 Targoni, O. S. and Lehmann, P. V. 1998. Endogenous myelin basic protein inactivates the high avidity T cell repertoire. *J. Exp. Med.* 187:2055.
- 61 Constant, S., Pfeiffer, C., Woodard, A., Pasqualini, T. and Bottomly, K. 1995. Extent of T cell receptor ligation can determine the functional differentiation of naive CD4⁺ T cells. *J. Exp. Med.* 182:1591.
- 62 de Jong, E. C., Vieira, P. L., Kalinski, P., Schuitemaker, J. H., Tanaka, Y., Wierenga, E. A., Yazdanbakhsh, M. and Kapsenberg, M. L. 2002. Microbial compounds selectively induce T_H1 cell-promoting or T_H2 cell-promoting dendritic cells *in vitro* with diverse T_H cell-polarizing signals. *J. Immunol.* 168:1704.
- 63 Le Gros, G., Ben-Sasson, S. Z., Seder, R., Finkelman, F. D. and Paul, W. E. 1990. Generation of interleukin 4 (IL-4)-producing cells *in vivo* and *in vitro*: IL-2 and IL-4 are required for *in vitro* generation of IL-4-producing cells. *J. Exp. Med.* 172:921.
- 64 Seder, R. A., Paul, W. E., Davis, M. M. and Fazekas de St Groth, B. 1992. The presence of interleukin 4 during *in vitro* priming determines the lymphokine-producing potential of CD4⁺ T cells from T cell receptor transgenic mice. *J. Exp. Med.* 176:1091.
- 65 Seder, R. A. and Paul, W. E. 1994. Acquisition of lymphokine-producing phenotype by CD4⁺ T cells. *Annu. Rev. Immunol.* 12:635.
- 66 Seder, R. A., Marth, T., Sieve, M. C., Strober, W., Letterio, J. J., Roberts, A. B. and Kelsall, B. 1998. Factors involved in the differentiation of TGF-beta-producing cells from naive CD4⁺ T cells: IL-4 and IFN-gamma have opposing effects, while TGF-beta positively regulates its own production. *J. Immunol.* 160:5719.
- 67 Kopf, M., Le Gros, G., Bachmann, M., Lamers, M. C., Bluethmann, H. and Kohler, G. 1993. Disruption of the murine IL-4 gene blocks T_H2 cytokine responses. *Nature* 362:245.
- 68 Falcone, M., Rajan, A. J., Bloom, B. R. and Brosnan, C. F. 1998. A critical role for IL-4 in regulating disease severity in experimental allergic encephalomyelitis as demonstrated in IL-4-deficient C57BL/6 mice and BALB/c mice. *J. Immunol.* 160:4822.
- 69 Shaw, M. K., Lorens, J. B., Dhawan, A., DalCanto, R., Tse, H. Y., Tran, A. B., Bonpane, C., Eswaran, S. L., Brocke, S., Sarvetnick, N., Steinman, L., Nolan, G. P. and Fathman, C. G. 1997. Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. *J. Exp. Med.* 185:1711.
- 70 Racke, M. K., Bonomo, A., Scott, D. E., Cannella, B., Levine, A., Raine, C. S., Shevach, E. M. and Rocken, M. 1994. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. *J. Exp. Med.* 180:1961.
- 71 Shaw, M. K., Kim, C., Hao, H. W., Chen, F. and Tse, H. Y. 1996. Induction of myelin basic protein-specific experimental autoimmune encephalomyelitis in C57bl/6 mice—mapping of T cell epitopes and T cell receptor V-beta gene segment usage. *J. Neurosci. Res.* 45:690.
- 72 Panitch, H. S., Hirsch, R. L., Schindler, J. and Johnson, K. P. 1987. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. *Neurology* 37:1097.
- 73 Panitch, H. S. 1992. Interferons in multiple sclerosis. A review of the evidence. *Drugs* 44:946.
- 74 Knobler, R. L., Greenstein, J. I., Johnson, K. P., Lublin, F. D., Panitch, H. S., Conway, K., Grant-Gorsen, S. V., Muldoon, J., Marcus, S. G., Wallenberg, J. C. and et al. 1993. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. *J. Interferon Res.* 13:333.
- 75 Wildbaum, G., Youssef, S., Grabie, N. and Karin, N. 1998. Neutralizing antibodies to IFN-gamma-inducing factor prevent experimental autoimmune encephalomyelitis. *J. Immunol.* 161:6368.
- 76 Krakowski, M. and Owens, T. 1996. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. *Eur. J. Immunol.* 26:1641.
- 77 Ferber, I. A., Brocke, S., Tayloredwards, C., Ridgway, W., Dinisco, C., Steinman, L., Dalton, D. and Fathman, C. G. 1996. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). *J. Immunol.* 156:5.
- 78 Brocke, S., Gijbels, K., Allegretta, M., Ferber, I., Piercy, C., Blankenstein, T., Martin, R., Utz, U., Karin, N., Mitchell, D., et al. 1996. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. *Nature* 379:343.
- 79 Tran, E. H., Prince, E. N. and Owens, T. 2000. IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. *J. Immunol.* 164:2759.
- 80 Fox, J. G., Beck, P., Dangler, C. A., Whary, M. T., Wang, T. C., Shi, H. N. and Nagler-Anderson, C. 2000. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy. *Nat. Med.* 6:536.
- 81 Marshall, A. J., Brunet, L. R., van Gessel, Y., Alcaraz, A., Bliss, S. K., Pearce, E. J. and Denkers, E. Y. 1999. *Toxoplasma gondii* and *Schistosoma mansoni* synergize to promote hepatocyte dysfunction associated with high levels of plasma TNF-alpha and early death in C57BL/6 mice. *J. Immunol.* 163:2089.
- 82 Steinman, L. 1997. Some misconceptions about understanding autoimmunity through experiments with knockouts. *J. Exp. Med.* 185:2039.
- 83 Butterworth, A. E., Dunne, D. W., Fulford, A. J., Thorne, K. J., Gachui, K., Ouma, J. H. and Sturrock, R. F. 1992. Human immunity to *Schistosoma mansoni*: observations on mechanisms, and implications for control. *Immunol. Invest.* 21:391.
- 84 Oro, A. S., Guarino, T. J., Driver, R., Steinman, L. and Umetsu, D. T. 1996. Regulation of disease susceptibility: decreased prevalence of IgE-mediated allergic disease in patients with multiple sclerosis. *J. Allergy Clin. Immunol.* 97:1402.
- 85 Tang, L., Benjaponpitak, S., DeKruyff, R. H. and Umetsu, D. T. 1998. Reduced prevalence of allergic disease in patients with multiple sclerosis is associated with enhanced IL-12 production. *J. Allergy Clin. Immunol.* 102:428.